2.5 semaglutide Flex-Dose 2 mL Injectable mg/mL Semaglutide 2mL Vial – Le

Three authors (K.B., C.B., L.M.) selected the final studies included in the meta-analysis based on the following criteria

Bleeding Disorders: Use cautiously if taking blood-thinning medications

The scale of accidental overdosing has been striking

4-6% placebo Diarrhea: 12-17% Vomiting: 5-10% Constipation: 6-11% Decreased appetite: 5-11% GI events are predominantly mild-moderate and occur mainly during dose escalation (first 4-8 weeks), with significant attenuation over time Serious adverse events of interest : Pancreatitis : Adjudicated pancreatitis events occurred at rates of approximately 0.1-0.2% across the SURPASS program, comparable to rates seen with GLP-1 agonists